Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04274179
Other study ID # IRB00241856
Secondary ID
Status Recruiting
Phase Phase 3
First received
Last updated
Start date August 10, 2020
Est. completion date May 1, 2025

Study information

Verified date August 2023
Source Johns Hopkins University
Contact Eric H Kossoff, MD
Phone 4109559100
Email ekossoff@jhmi.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The ketogenic diet is a medical therapy for epilepsy that is used nearly predominantly for refractory epilepsy (after 2-3 drugs have been tried and failed). However, there is both published evidence for first-line use (infantile spasms, Glut1 deficiency syndrome) and also anecdotal experience (families choosing to change the child's (or the family' own) diet rather than use anticonvulsant medications). Childhood absence epilepsy (refractory) has been published as being responsive to ketogenic diet therapy by the investigators' group previously. This is a small, prospective, 3 month trial to assess if using a modified Atkins diet is a feasible and effective option for new-onset childhood absence epilepsy. The investigators will compare to a group of children in which the parents have declined and chose to start anticonvulsant medications.


Description:

The ketogenic diet has been in continuous use since 1921 for children and adult with medically-refractory epilepsy. One of the major unanswered questions is whether it would be as effective for children with new-onset epilepsy. Although logically, this would be the case, it remains to be shown in clinical trials. Additionally, it is much easier to take a medication than to change dietary habits and there is doubt whether families would truly wish to try dietary therapy first (or stay on dietary therapy if not effective for a 6 month trial period). There is limited published evidence supporting the use of the ketogenic diet as a first-line therapy for infantile spasms, myoclonic astatic epilepsy, and in some situations where a family member had success and the family wishes to start it first. However, these are relatively rare conditions. The emergence of the modified Atkins diet as an outpatient, quickly-initiated, non-fasting approach since 2003 has changed the concept of dietary therapy towards a much less restrictive, potentially emergent therapy. In this way, using dietary therapy could potentially be started before medications for a willing family. The use of dietary therapy (including the modified Atkins diet) for childhood absence epilepsy goes back decades, but was recently profiled in a review article from the investigators' group. In this publication, 17 studies were identified, and 69% of 133 children with refractory childhood absence epilepsy had a >50% seizure reduction and 34% were seizure-free. At the investigators' center, 21 children as of 2011 had been treated with dietary therapy with 19% seizure-freedom. The question of whether results would be similar (or better) for children with new-onset absence epilepsy was unanswered. The standard treatments for childhood absence epilepsy (ethosuximide, valproate, lamotrigine) are effective in ~50% of children by 16-20 weeks. However, side effects exist and include stomach upset, inattention, mood disturbance, rash, liver function test abnormalities, and fatigue. Families at times do ask about avoiding treatment completely, especially as this epilepsy usually resolves in puberty and convulsions only occur in 20% (most children have brief staring spells only). In addition, families do also ask about "nonpharmacologic" treatment, but to date the investigators have not recommended it due to lack of data. This study will have 20 children in each arm (diet and drug) with ability to crossover. Parents with a child with new-onset absence epilepsy will choose between the two therapies. Visits will be at baseline, 1 month and 3 months. EEG, labs and clinic visits will be paid by the parent's insurance (not free).


Recruitment information / eligibility

Status Recruiting
Enrollment 40
Est. completion date May 1, 2025
Est. primary completion date May 1, 2025
Accepts healthy volunteers No
Gender All
Age group 3 Years to 12 Years
Eligibility Inclusion Criteria: - Children ages 3-12 years at seizure onset with classic childhood absence epilepsy clinically. - Normal intellect or mild disability - EEG with confirmed 3/second spike-wave discharges, usually with hyperventilation - Daily reported absence seizures. - Generalized convulsions allowed Exclusion Criteria: - Previous treatment with any anticonvulsant drug - Previous use of a ketogenic dietary therapy for epilepsy or any other condition - Glut1 deficiency syndrome - Metabolic disorder known that would preclude dietary therapy - Dietary restrictions for which a high fat, low carbohydrate diet would be precluded. - Prior history of epilepsy (febrile seizures allowed) - Unwilling to consent to study procedures or return for visits

Study Design


Intervention

Other:
Modified Atkins Diet
Low carb (20g/day), high fat, moderate protein diet. Started as an outpatient in clinic.
Drug:
Absence epilepsy medications
At neurologist's discretion. *OF NOTE< THIS ARM IS COMPLETED

Locations

Country Name City State
United States Johns Hopkins Hospital Baltimore Maryland

Sponsors (1)

Lead Sponsor Collaborator
Johns Hopkins University

Country where clinical trial is conducted

United States, 

References & Publications (2)

Groomes LB, Pyzik PL, Turner Z, Dorward JL, Goode VH, Kossoff EH. Do patients with absence epilepsy respond to ketogenic diets? J Child Neurol. 2011 Feb;26(2):160-5. doi: 10.1177/0883073810376443. Epub 2010 Jul 20. — View Citation

Kossoff EH, Hedderick EF, Turner Z, Freeman JM. A case-control evaluation of the ketogenic diet versus ACTH for new-onset infantile spasms. Epilepsia. 2008 Sep;49(9):1504-9. doi: 10.1111/j.1528-1167.2008.01606.x. Epub 2008 Apr 10. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Change in seizure frequency Parental report of seizure frequency. At 1 and 3 months post treatment
Secondary Tolerability of diet therapy as assessed by restrictiveness of the diet therapy Diet therapy restrictiveness will be assessed with an open ended questionnaire that asks "how hard has it been for the child?". Completely subjective with no scale or scoring. At 3 months
Secondary Tolerability of diet therapy as assessed by restrictiveness of the diet therapy Diet therapy restrictiveness will be assessed with an open ended questionnaire that asks "how hard has it been for the child?". Completely subjective with no scale or scoring. At 6 months
Secondary Duration of diet therapy Duration of diet therapy in months. Up to 3 months post treatment
Secondary Tolerability of diet therapy as assessed by change in urinary ketones Urinary ketones in mg/dl will be measured (80-160mg/dl is considered large ketosis). At 1 and 3 months post treatment
Secondary EEG changes (normalization of the baseline spike-wave bursts) 30 minute routine EEG including hyperventilation to induce seizures, compare 3 months to baseline Baseline and at 3 months post treatment
See also
  Status Clinical Trial Phase
Recruiting NCT06115265 - Ketogenic Diet and Diabetes Demonstration Project N/A
Completed NCT03141008 - Evaluation of Liver and Cardiometabolic Health Benefits on Low Carbohydrate Ketogenic Diet
Terminated NCT03790436 - Betaquik as an Adjunct to Dietary Management of Epilepsy in Adults on the Modified Atkins Diet N/A
Not yet recruiting NCT06013397 - Effectiveness of Ketogenic Diet in MELAS Syndrome N/A
Recruiting NCT05689580 - The Influence of Ketogenic Diet on Lupus Nephritis Patients' Immunity N/A
Recruiting NCT04492228 - Eucaloric Ketogenic Diet in COVID-19 Cytokine Storm Syndrome N/A
Completed NCT05603689 - Effect of Isocaloric Ketogenic Diet on Physical Performance at High Altitude N/A
Completed NCT04744558 - Low Carbohydrate High Fat Ketogenic vs. Non-ketogenic Diet N/A
Completed NCT04108819 - Ketogenic Diet for Obesity Hypoventilation Syndrome N/A
Completed NCT04130724 - Characterization of a Portable Solid-State Breath Acetone Testing Device for Real-Time Ketosis Status
Enrolling by invitation NCT05049954 - Weight Loss for a Healthier You Programme N/A
Recruiting NCT03564002 - Metabolic Effects of Very Low Carbohydrate Ketogenic Diet in Subjects With Severe Obesity
Recruiting NCT05591508 - Ketogenic Diet for Status Epilepticus in Children Post Cessation of Convulsive Status Epilepticus N/A
Completed NCT04112862 - Sodium Lactate Infusion in GLUT1DS Patients Early Phase 1
Recruiting NCT03991897 - Ketogenic Diet: a Novel Metabolic Strategy to Treat Lymphedema Patients? N/A
Withdrawn NCT03202108 - Evaluation of Krio in Children and Adults With Epilepsy N/A
Completed NCT05012748 - The Effects of Ketogenic Diet on the Heart and Brain N/A
Completed NCT03982602 - Ketogenic Diet for Traumatic Brain Injury Early Phase 1
Recruiting NCT06022796 - Weight Loss Interventions for Obesity N/A
Completed NCT05219006 - Ketogenic Diet Effects on the Frequency of Non Epileptic Seizures N/A